Situación actual de los SYSADOA en España

Pineda, Miguel Bernad

doi:10.1016/j.reuma.2016.03.012

Cited by 6 publications

(8 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In fact, CS and glucosamine were not associated with an increased risk of adverse effects (AE) compared to placebo. 17 This good tolerability of CS contrasts with the toxicity problems described for NSAIDs/COXIBs 18 at gastrointestinal, 19 cardiovascular 20 and renal 21 levels.…”

Section: Introductionmentioning

confidence: 99%

<p>Analysis of the Health and Budgetary Impact of Chondroitin Sulfate Prescription in the Treatment of Knee Osteoarthritis Compared to NSAIDs and COXIBs</p>

Rubio-Terrés

Pineda²,

Herrero³

et al. 2020

CEOR

Self Cite

View full text Add to dashboard Cite

Background Chondroitin sulfate, alone or associated with glucosamine (CS), is an effective treatment of osteoarthritis, better tolerated than non-steroidal anti-inflammatory drugs (NSAIDs) and cyclooxygenase 2 inhibitors (COXIBs) at gastrointestinal, cardiovascular and renal levels. Objective To estimate the health impact (toxicity by NSAIDs/COXIBs avoided with CS with or without glucosamine) and economic impact (savings due to avoided toxicities) of treatment of knee osteoarthritis with CS compared to NSAIDs/COXIBs, as a consequence of the avoidance of mild-moderate or severe gastrointestinal adverse effects (GIAE), ischaemic heart disease (IHD), acute kidney insufficiency (AKI) and chronic kidney failure (CKF). Methods We compared the current situation (available reimbursed prescription with CS) with a hypothetical situation without CS (treatment only with NSAIDs/COXIBs). The frequency of GIAE, IHD, AKI and CKF with CS and NSAIDs/COXIBs was obtained from published ad hoc studies. The cost of AE management and of the drugs (180 days of treatment) was obtained from Spanish sources. A probabilistic economic model was made for a 3-year period, both at national (NHS) and regional levels. Sensitivity analyses were performed for different durations of treatment (90 and 240 days). Results In Spain, it is estimated that 519,130, 513,616 and 507,377 patients with knee osteoarthritis will be treated with NSAIDs/COXIBs and 112,775, 114,963 and 117,262 with CS in 2020, 2021 and 2022, respectively. Due to better CS tolerability, 55,098 mild-moderate GIAE, 3060 severe GIAE, 204 IHD, 1089 AKI and 733 CKF would be avoided in 3 years. Discounting the cost of the drugs, the three-year savings for the NHS would be 21.8 (12.7–29.5) million euros. Conclusion Due to its better tolerability profile, CS treatment is expected to prevent thousands of AEs over the next 3 years, some of which may be life-threatening for patients, while generating considerable savings for the NHS.

show abstract

Section: Introductionmentioning

confidence: 99%

<p>Analysis of the Health and Budgetary Impact of Chondroitin Sulfate Prescription in the Treatment of Knee Osteoarthritis Compared to NSAIDs and COXIBs</p>

Rubio-Terrés

Pineda²,

Herrero³

et al. 2020

CEOR

Self Cite

View full text Add to dashboard Cite

show abstract

“…Osteoarthritis (OA) is one of the major cause of pain and disability in the adult population (1) . It is a degenerative disease that affects joints and surrounding tissue of the hips, hands, knees and spine (2,3) . Disease progression causes gradual loss of quality of life, leading to pain, stiffness, swelling, effusion and crepitus in the affected joints (4) .…”

Section: Introductionmentioning

confidence: 99%

“…OA is currently a challenge for healthcare systems as its incidence is increasing due to population ageing (2,4,5) . The main goal of OA treatment is to reduce pain, disability and ultimately, to avoid joint replacement surgery (6) .…”

Section: Introductionmentioning

confidence: 99%

“…Given the safety problems associated with long-term use of acetaminophen and non-steroidal anti-inflammatory drugs (NSAIDs) (2,7,8) , and the characteristics of the disease and of patients with OA (generally elderly, polymedicated and with comorbidities), it seems necessary to incorporate more tolerable agents in the non-acute therapy of OA (4,7) .…”

Section: Introductionmentioning

confidence: 99%

“…Chondroprotection remains after treatment discontinuation due to a carry-over effect (3,6,12,14) . CS efficacy has been widely discussed and its public financing by the Spanish National Health System has been questioned (2,15). The aim of this paper was to perform a narrative review of the literature published in the last 5 years regarding the clinical and economics aspects of CS in the management of OA.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Clinical and economic aspects of chondroitin sulfate in osteoarthritis management: a brief review of recent evidence

2022

View full text Add to dashboard Cite

Introduction: Chondroitin sulfate was proposed as a more appropriate strategy for osteoarthritis long-term management than conventional treatment (nonsteroidal anti-inflammatory drugs and acetaminophen). However, its efficacy has been widely discussed and its public financing by the Spanish National Health System has been questioned. The aim of this paper was review on the clinical and economic aspects of chondroitin sulfate in osteoarthritis treatment. Method: A bibliographic search of recent literature was carried out until March 9th, 2022. The databases used were MEDLINE and Scopus. Results: According to the set of clinical studies identified in the search, chondroitin sulfate was effective in reducing cartilage volume loss, its clinical effects were estimated by objective (magnetic resonance or specific biomarkers) and subjective (visual analog pain scale or Lequesne index) outcome measures. In the set of studies reviewed, chondroitin sulfate proved to be an acceptable therapeutic option in clinical terms. Regarding economic aspects, only one study was identified, according to which, the prescription of chondroitin sulfate implies a lower cost per patient compared to non-steroidal anti-inflammatory drugs. Conclusion: From the clinical and economic points of view, the findings of this brief review justify the presence of chondroitin sulfate in osteoarthritis guidelines.

show abstract

Diagnóstico y tratamiento de la patología del hombro en atención primaria

Bascuñana¹

2018

FMC - Formación Médica Continuada en Atención Primaria

View full text Add to dashboard Cite

Situación actual de los SYSADOA en España

Cited by 6 publications

References 17 publications

<p>Analysis of the Health and Budgetary Impact of Chondroitin Sulfate Prescription in the Treatment of Knee Osteoarthritis Compared to NSAIDs and COXIBs</p>

<p>Analysis of the Health and Budgetary Impact of Chondroitin Sulfate Prescription in the Treatment of Knee Osteoarthritis Compared to NSAIDs and COXIBs</p>

Clinical and economic aspects of chondroitin sulfate in osteoarthritis management: a brief review of recent evidence

Diagnóstico y tratamiento de la patología del hombro en atención primaria

Contact Info

Product

Resources

About